Pharmacy Times interviews Renee’ Acosta, R.Ph., M.S., on how pharmacy technicians can recognize when patients should be referred to a pharmacist or physician instead of self-treating with OTC products, and how to help patients avoid risks associated with combination products such as duplicate ingredients.
New CMS prior authorization timelines highlight major infrastructure gaps while underscoring the link between access, affordability, and medication adherence.
FDA approval of orforglipron may expand access to obesity treatment by offering a more convenient oral GLP-1 therapy option.
Explore evolving endometrial cancer treatments: HER2-targeted trastuzumab, ADCs, and immunotherapy sequencing, plus NCCN guidance for dMMR and pMMR.
The panelists examined the broadening treatment landscape beyond PD-1 inhibitors, highlighting the significant role of trastuzumab in human epidermal growth receptor 2 (HER2)–overexpressing uterine serous and carcinosarcoma subtypes.
Optimizing biomarker testing workflows and pharmacist involvement can improve precision oncology decision-making in non–small cell lung cancer.
New NCCN updates make sacituzumab govitecan a preferred first-line option in metastatic TNBC. Jordan Hill, PharmD, BCOP, explains the impact.
Remote therapeutic monitoring (RTM) improves patient outcomes, reduces hospitalizations, and supports sustainable oncology care delivery.
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, from the University of Kansas Cancer Center talks about bispecifics and the value of building a network to communicate operationalizing these therapies across clinics.
Andel's direct-to-employer model partners with Eli Lilly and other pharma companies to offer flexible, insurance-free GLP-1 access that benefits employers, patients, and manufacturers.
Renee’ Acosta, RPh, MS, discusses recent developments in the OTC market and key considerations pharmacy staff should prioritize when guiding patients in selecting appropriate over-the-counter therapies.
Pharmacists help prevent communication breakdowns and improve coordination across oncology care teams.
Panelists examine how LDL-C targets vary by cardiovascular risk level and highlights the role of pharmacists and multidisciplinary teams in delivering effective patient education to improve adherence and long-term outcomes.
Panelists explore how treatment goals differ between primary and secondary cardiovascular prevention, emphasizing risk stratification, guideline application, and strategies to optimize long-term outcomes through individualized, multidisciplinary care.
Coordinated pharmacist-led outreach, e-consults, and continuous glucose monitoring support improve diabetes outcomes, increase guideline-based therapy use, and impact total cost of care.
The need for data-driven, multidisciplinary care and the critical role of pharmacists in managing the growing complexity of oncology treatment
Pharmacists are enabling the shift to outpatient bispecific antibody care through education, SOP development, and care coordination.
Cardinal Health’s 2026 Advanced Therapies Report found strong provider momentum for expanding advanced therapy administration into community settings.
Pharmacists are central to implementing bispecific antibody therapies through clinical expertise, operational leadership, and care coordination.
Pharmacists support evidence-based treatment decisions, coordinate multidisciplinary care, and optimize precision oncology outcomes.
Integrated EMR systems and coordinated pharmacy operations can streamline biomarker-driven treatment decisions and improve patient outcomes.
Pharmacists can help standardize biomarker testing and improve access to targeted therapies in non–small cell lung cancer.
Pharmacists can help optimize TKI therapy in CML through education, adherence support, toxicity monitoring, and collaboration with care teams.
Bispecific antibodies are reshaping multiple myeloma care through improved safety and expanded outpatient use.
Integrated health plan–provider collaboration enables pharmacists to drive proactive diabetes management, improve adherence, and expand access to CGM and lifestyle support.
Combining AI-driven insights with human-first outreach can overcome the emotional and behavioral barriers driving specialty medication nonadherence.
Clinicians compare PD-1 immunotherapies in endometrial cancer, weighing trial differences, progression-free survival, response rates, toxicity, and long-term quality of life.
Overall survival (OS) guides first-line endometrial cancer choices, as RUBY trial data show mature dostarlimab benefit, while pembrolizumab OS is pending.
This week's episode highlights a new executive order signed by President Trump, new expanded FDA approvals, and a conference roundup.
Rapport Therapeutics' RAP-219 achieved seizure freedom in 24% of patients with drug-resistant focal epilepsy over 8 weeks in a phase 2 trial.
